WC
ARQT icon

Wexford Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Wexford Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,849
Closed -$72.5K – 389
2025
Q3 		$72.5K Sell
3,849
-7,709
-67% -$122K 0.01% 265
2025
Q2 		$162K Buy
+11,558
New +$162K 0.05% 180

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wexford Capital's ARQT Position: Q4 2025 in Review

Wexford Capital sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 3,849 shares — an estimated $72.5K sold.

Wexford Capital first reported a position in ARQT in Q2 2025 and held it in 2 quarters. The position peaked at $162K in Q2 2025. 283 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • Wexford Capital reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 3,849 Arcutis Biotherapeutics shares in Q4 2025, an estimated $72.5K.
  • Wexford Capital first reported a position in Arcutis Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • Wexford Capital's Arcutis Biotherapeutics position peaked at $162K in Q2 2025.
  • 283 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.